Literature DB >> 18779626

Pseudoprogression in glioblastoma.

Marc C Chamberlain.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18779626     DOI： 10.1200/JCO.2008.18.4440

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  28 in total

1.  Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.

Authors:  C H Suh; H S Kim; Y J Choi; N Kim; S J Kim
Journal:  AJNR Am J Neuroradiol       Date:  2013-07-04       Impact factor: 3.825

Review 2.  Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.

Authors:  L C Hygino da Cruz; I Rodriguez; R C Domingues; E L Gasparetto; A G Sorensen
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-10       Impact factor: 3.825

3.  Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.

Authors:  D-S Kong; S T Kim; E-H Kim; D H Lim; W S Kim; Y-L Suh; J-I Lee; K Park; J H Kim; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-20       Impact factor: 3.825

4.  [Prediction of clinical course of glioblastomas by MRI during radiotherapy].

Authors:  Christina Leitzen; Hans H Schild; Birgitta Bungart; Ulrich Herrlinger; Christiana Lütter; Thomas Müdder; Timo Wilhelm-Buchstab; Heinrich Schüller
Journal:  Strahlenther Onkol       Date:  2010-11-29       Impact factor: 3.621

5.  Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma.

Authors:  Florian Stockhammer; Martin Misch; Arend Koch; Marcus Czabanka; Michail Plotkin; Cristiane Blechschmidt; Jochen Tuettenberg; Peter Vajkoczy
Journal:  J Neurooncol       Date:  2010-05-06       Impact factor: 4.130

6.  Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis.

Authors:  J Cha; S T Kim; H-J Kim; B-J Kim; Y K Kim; J Y Lee; P Jeon; K H Kim; D-S Kong; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2014-03-27       Impact factor: 3.825

7.  Measuring clinical benefit: use of patient-reported outcomes (PRO) in primary brain tumor clinical trials.

Authors:  Terri S Armstrong
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

8.  Diffusion abnormalities of the corpus callosum in patients receiving bevacizumab for malignant brain tumors: suspected treatment toxicity.

Authors:  Stephen F Futterer; Alexander J Nemeth; Sean A Grimm; Ann B Ragin; James P Chandler; Kenji Muro; Maryanne H Marymont; Jeffrey J Raizer
Journal:  J Neurooncol       Date:  2014-02-28       Impact factor: 4.130

Review 9.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

Review 10.  Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.

Authors:  Terri S Armstrong; Mark R Gilbert
Journal:  Curr Treat Options Oncol       Date:  2014-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.